Table 1.
Overview of included trials. * = baseline characteristics from SMAC meta-analysis.
| Trial | Year | N Total |
Med. AGE |
Female | FU (y) |
Site | G3+ | Exp. Arm |
n | Contr. Arm |
n | Surgery | RT | CTx |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GOG (Omura) [25] | 1997 | 225 | n.a. | 100% | 9.4 * | U | 67% * | adCTx | 113 | S ± RT | 112 | HE | n.a. | D |
| MDA (Benjamin) [6,26] | 1997 | 54 | n.a. | 54% * | 9.4 * | Extr.,T | 67% * | adCTx | 26 | S ± RT | 28 | n.a. | n.a. | D + C + ACTD + V |
| Mayo (Edmonson) [27,28] | 1997 | 57 | n.a. | 54% * | 9.4 * | Extr., T | 67% * | adCTx | 28 | S ± RT | 29 | n.a | n.a. | D + V + ACTD + DTIC |
| NCI4 (Rosenberg/Chang) [29,30] | 1997 | 25 | n.a. | 54% * | 9.4 * | Extr. | 67% * | adCTx | 17 | S ± RT | 8 | Amp or WE | 45–70 Gy | D + C + MTX |
| NCI5 (Glenn) [31,32] | 1997 | 79 | n.a. | 54% * | 9.4 * | T, HN, RP, B | 67% * | adCTx | 38 | S ± RT | 41 | WE | 60–63 Gy | D + C + MTX |
| NCI6 (Rosenberg/Chang) [29,30] | 1997 | 41 | n.a. | 54% * | 9.4 * | Extr. | 67% * | adCTx | 21 | S ± RT | 20 | n.a. | n.a. | D + C + MTX |
| EORTC (Bramwell) [16] | 1997 | 467 | n.a. | 54% * | 9.4 * | Extr., T, HN | 67% * | adCTx | 234 | S ± RT | 233 | n.a. | 40–50 Gy | D + C + V + DTIC |
| DFCI/MGH (Antman) [33] | 1997 | 46 | n.a. | 54% * | 9.4 * | Extr. T, HN, RP | 67% * | adCTx | 21 | S ± RT | 25 | Amp or WE | 62.5–67.5 Gy | D |
| ECOG (Lerner) [34] | 1997 | 47 | n.a. | 54% * | 9.4 * | Extr., T, HN, RP | 67% * | adCTx | 24 | S ± RT | 23 | Amp or WE | 50–64 Gy | D |
| Bergonie (Ravaud) [35] | 1997 | 65 | n.a. | 54% * | 9.4 * | Extr., T, HN, RP | 67% * | adCTx | 33 | S ± RT | 32 | n.a. | n.a. | D + C + V + DTIC |
| SSG (Alvegard) [36] | 1997 | 240 | 57 | 49% | 9.4 * | Extr., T, HN, B, Tx, Abd. | 100% | adCTx | 121 | S ± RT | 119 | WE | 42–51 Gy | D |
| Rizzoli (Gherlinzoni/Picci) [37,38] | 1997 | 77 | n.a. | 54% * | 9.4 * | Extr. | 67% * | adCTx | 34 | S ± RT | 43 | WE | 45 Gy | D |
| IGSC (Baker/Antman) [39,40] | 1997 | 92 | n.a. | 54% * | 9.4 * | Extr., T, HN, RP | 67% * | adCTx | 43 | S ± RT | 49 | n.a. | n.a. | D |
| SAKK [6] | 1997 | 29 | n.a. | 54% * | 9.4 * | Extr., T | 67% * | adCTx | 14 | S ± RT | 15 | n.a. | n.a. | D + IFO |
| Pautier [41] | 2013 | 81 | 55 | 100% | 4.3 | U | n.a. | adCTx | 39 | S + RT | 42 | n.a. | 45/1.8 Gy | D + IFO + CDDP |
| Woll [8] | 2012 | 351 | 49 | 45% | 8 | Extr., T, HN | 46% | adCTx | 175 | S ± RT | 176 | n.a. | 50–66 Gy | D + IFO |
| Fakrai [42] | 2010 | 58 | 52 | 46% | 8.1 | Extr., T, RP | 73% | adCTx | 31 | S + RT | 27 | “adequate” | 51/1.7 Gy | D + IFO + DTIC |
| Frustaci [43,44] | 2001/2003 | 104 | n.a. | 41% | 4.9 | Extr., T | 100% | adCTx | 53 | S ± RT | 51 | HE | 44.8–66 Gy | EPI + IFO |
| Petrioli [45] | 2002 | 88 | 53 | 49% | 7.8 | Extr., T, Abd., RP | 41% | adCTx | 45 | S ± RT | 43 | WE | 54–60 Gy | EPI + IFO |
| Hensley [46] | 2018 | 38 | n.a. | 100% | 4.3 | U | 100% | adCTx | 20 | S | 18 | HE | n.a. | TXT + GEM + D |
| Issels [21,22] | 2018 | 341 | 52 | 44% | 11.3 | Extr., T, HN | 53% | NaCTx+HTx | 162 | NaCTx | 167 | n.a | 50–66 Gy | D + IFO |
| Gronchi [23,24] | 2017/-20 | 286 | 40 | 38% | 4.3 | Extr., T, Abd. | 100% | HtCTx | 142 | NaCTx | 144 | n.a | 44–66 Gy | EPI + IFO |
| Gortzak [18] | 2001 | 134 | 53 | 40% | 7.3 | Extr., T, HN | n.a. | NacCTx | 67 | S ± RT | 67 | Amp or WE | 60–80 Gy | D + IFO |
| Gronchi [20,47] | 2016 | 321 | 49 | n.a. | 9.75 | Extr., T | n.a. | NaCTx | 161 | periCTx | 160 | n.a | 44–66 Gy | EPI + IFO |
| Eilber [19] | 1988 | 119 | 59 | 45% | 2.3 | Extr. | 100% | periCTx | 57 | RT + S | 62 | Amp or WE | 17.5/3.5 Gy | D |
Abbreviations: n.a. = not available, adCTx = adjuvant chemotherapy, NaCTx + HTx = neoadjuvant chemotherapy and hyperthermia, NaCTx = neoadjuvant chemotherapy, HtCTx = histology tailored chemotherapy, periCTx = perioperative chemotherapy, HE = hysterectomy, Amp = amputation, WE = wide excision, Gy = gray, G3+ = grade 3 or higher, FU = follow-up, D = Doxorubicine, C = Cyclosphosphamid, ACTD = Dactinomycin; V = Vincristine; DTIC = Dacarbazine; MTX = Methotrexate; IFO = Ifosfamide, CDDP = Cisplatin, GEM = gemcitabine, EPI = Epirubicin, TXT = docetaxel, T = Trunk, B = Breast; RP = Retroperitoneal, Abd = Abdominal; U = Uterus; HN = head and neck, and Tx = Thorax, y = year; Patients in the treated in the arms with systemic treatment were intended to receive local therapy as well.